"In the year 2011, data of a total of 313,604 therapies (without one-off contacts) carried out in N=778 outpatient facilities were collected within the framework of the DSHS. For this REITOX Report only data from clients primarily treated for illicit substance use (including sedatives/hypnotics and volatile solvents) were taken into account (patients treated primarily for alcohol-induced disorders accounted alone for 54% of all recorded cases in 2011).
"Diagnostic data
"For the year 2011, the German Statistical Report on Treatment Centres for Substance Use Disorders contains data on the main diagnoses of a total of 60,169 treatments from N=778 facilities that were started or completed in outpatient psychosocial addiction support centres because of problems with illicit drugs. The main diagnoses are based on the diagnostic categories of the international classification system of the World Health Organisation (WHO), the ICD 10, for disorders caused by psychotropic substances (harmful use or dependence).
"When looking at the DSHS data and confining oneself to illicit substances, one finds that less than half of the clients (44.9%; 2010: 46.3%) sought treatment or counselling primarily for dependence on or harmful use of opioids90. The proportion of persons primarily treated for disorders in connection with the use of opioids has been on a continual decline since 2007. In more than a third of the cases (34.7%; 2010: 35.6%), clients were treated for primary cannabis problems. After having increased over the last years, this portion has stabilised. On the rise is the proportion of clients who receive counselling and treatment because of problems connected to the use of stimulants (10.5%; 2010: 8.2%). The comparative values for cocaine (5.8%; 2010: 5.9%) and other substances remained practically unchanged in comparison with the previous year."


German Reference Centre for the European Monitoring Centre for Drugs and Drug Addiction (Deutsche Beobachtungsstelle fuer Drogen und Drogensucht (DBDD)), "2012 National Report to the EMCDDA by the Reitox National Focal Point: Germany: New Developments, Trends and In-Depth Information on Selected Issues - Drug Situation 2011/2012" (Munich, Germany: DBDD, Oct. 2012), pp. 108-109.……